Antisense compounds, compositions and methods are provided for modulating the expression of vascular endothelial growth factor receptor-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding vascular endothelial growth factor receptor-2. Methods of using these compounds for modulation of vascular endothelial growth factor receptor-2 expression and for treatment of diseases associated with expression of vascular endothelial growth factor receptor-2 are provided.
Claims What is claimed is: 1. A compound 8 to 50 nucleobases in length targeted to nucleobases 53 through 187 or nucleobases 273 through 292 of a 5'-untranslated region, nucleobases 362 through 381, nucleobases 454 through 473, nucleobases 479 through 498, nucleobases 595 through 614, nucleobases 772 through 791, nucleobases 799 through 818, nucleobases 827 through 846, nucleobases 2500 through 2519, nucleobases 2557 through 2582, nucleobases 2621 through 2640, nucleobases 2663 through 2682, nucleobases 2686 through 2711, nucleobases 2716 through 2735, nucleobases 2825 through 2852, nucleobases 2663 through 2882, nucleobases 2910 through 2929, nucleobases 3187 through 3206, nucleobases 3292 through 3363, nucleobases 3414 through 3439, nucleobases 3593 through 3612, nucleobases 3700 through 3719, nucleobases 3802 through 3821, nucleobases 3254 through 3878, nucleobases 3883 through 3912, nucleobases 3931 through 3966, nucleobases 3978 through 3997, nucleobases 4004 through 4031, nucleobases 4095 through 4114, nucleobases 4132 through 4158, or nucleobases 4168 through 4187 of a coding region, nucleobases 4363 through 4382 of a stop codon region, or nucleobases 4399 through 5681 of a 3'-untranslated region of a nucleic acid molecule encoding vascular endothelial growth factor receptor-2 of SEQ ID NO: 3, wherein said compound comprises at least one modified internucleoside linkage, specifically hybridizes with one of said regions and inhibits the expression of vascular endothelial growth factor receptor-2. 2. The compound of claim 1 which is an antisense oligonucleotide. 3. The compound of claim 1 wherein the modified internucleoside linkage is a phosphorothioate linkage. 4. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety. 5. The compound of claim 4 wherein the modified sugar moiety is a 2'-o-methoxyethyl sugar moiety. 6. The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase. 7. The compound of claim 6 wherein the modified nucleobase is a 5-methylcytosine. 8. The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide. 9. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent. 10. The composition of claim 9 further comprising a colloidal dispersion system. 11. The composition of claim 9 wherein the compound is an antisense oligonucleotide. 12. A method of inhibiting the expression of vascular endothelial growth factor receptor-2 in cells or tissues comprising contacting said cells or tissues in vitro with the compound of claim 1 so that expression of vascular endothelial growth factor receptor-2 is inhibited. 